It is particularly noteworthy that ActRIIA-Fc treatment in severe experimental PAH reverses elevated pulmonary expression of Grem1, which encodes an endogenous BMP antagonist (gremlin-1) regarded as an important promoter of vascular remodeling in PAH38. The gene discussed is GREM1; the disease is pulmonary arterial hypertension.